EPCAM and cancer: Tucotuzumab celmoleukin (huKS-IL2), an immunocytokine that acts by genetically fusing interleukin-2 (IL-2) to a humanized monoclonal antibody against EpCAM [10], has demonstrated safety and immunologic activity in cancer patients [11].